Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
MSLE
SATELLOS BIOSCIENCE INC.
NASDAQ
$9.32
▼ DOWN 3.72% (-0.36)

KEY STATISTICS

Market Cap$12.01 M
52w High$13.39
52w Low$5.30
Dividend Yield—
Frequency—
P/E-4.85
Volume19.31K
Shares Out.1.29M

COMPANY

LEADERSHIP

Francis Gleeson
CHIEF EXECUTIVE
Francis Gleeson

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 3, 2012
METHOD OF GOING PUBLIC
Dual Listing
FULL TIME EMPLOYEES
18

PRICE TARGET

Target High$23.00
Target Low$18.00
Target Median$18.00
Target Consensus$19.67

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.—
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2026-01-30Reverse1:12

PRICE

$9.32 ▼ DOWN 3.72% (−$0.36)
OVERLAYS
$9.30$9.45$9.60$9.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM9.32

About Satellos Bioscience Inc.

https://satellos.com ↗

Satellos Bioscience, Inc. is a Toronto-based regenerative medicine company developing novel muscle therapeutics using its proprietary MyoReGenX™ platform to identify and address stem cell regeneration deficits.

INDUSTRY

Biotechnology

A PRODUCT SATELLOS BIOSCIENCE INC. IS KNOWN FOR

SAT-3247
SAT-3247

SAT-3247 is a Phase 2 oral small molecule drug by Satellos Bioscience aimed at restoring muscle repair in Duchenne muscular dystrophy patients.

COMPETITORS

COMPETITOR
CAPR COMPARE
DYN COMPARE
EWTX COMPARE
PTCT COMPARE
SRPT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
SURI
0.02% · 1.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
17.28%
HOLDERS
1
TOP 1 OF 1 · RANKED BY POSITION SIZE
Adar1 Capital Management, LLC
222.6K sh · $1.25M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book2
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY